PCN116 BUDGET-IMPACT ANALYSIS OF THE INTRODUCTION OF REGORAFENIB IN BRAZILIAN SUPPLEMENTARY HEALTHCARE SYSTEM AS A SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH SORAFENIB
Autor: | R. Palhares, B Pegoretti Rosa, Luciano Paladini, R. Saad, N. Bergamelli Ramos, E.P. Nardi, L. Yamamoto |
---|---|
Rok vydání: | 2019 |
Předmět: |
Oncology
Sorafenib medicine.medical_specialty Second line treatment business.industry Health Policy Public Health Environmental and Occupational Health Budget impact medicine.disease chemistry.chemical_compound chemistry Regorafenib Internal medicine Hepatocellular carcinoma medicine Previously treated business Healthcare system medicine.drug |
Zdroj: | Value in Health. 22:S77 |
ISSN: | 1098-3015 |
Databáze: | OpenAIRE |
Externí odkaz: |